New drug trial aims to quiet heart inflammation in sarcoidosis patients
NCT ID NCT06868381
First seen Feb 19, 2026 · Last updated Apr 30, 2026 · Updated 5 times
Summary
This early-phase trial tests whether baricitinib, taken with a steroid-sparing medication, can reduce inflammation in the hearts of adults with active cardiac sarcoidosis. Ten participants will take the drug for up to 16 weeks and undergo PET scans to measure changes in heart inflammation. The goal is to see if this combination can better control the disease without long-term steroid use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC SARCOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Stanford University
Palo Alto, California, 94304-2210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.